In January through March 2011, the company reported a net profit of RON19.4 million.
Zentiva, a unit of French drug maker Sanofi-Aventis, said total revenue rose 10.2% on the year to RON77.6 million in the first quarter, while overall costs increased 41.5% to RON67.6 million.
Sales advanced 12.4% on the year to RON72.7 million.
The company has a share capital of RON41.6 million split into 416.9 million shares with a face value of RON0.1.
French group Sanofi-Aventis owns 75% in Zentiva Romania.
Tuesday, Zentiva’s shares closed up 7.53% at RON0.7 in Bucharest, amid a declining market. (EUR1=RON4.4411)